INCY News and Press, Incyte Corporation From 05/11/21

Incyte (NASDAQ:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHO...

Incyte Corporation (INCY) Q1 2021 Earnings Conference Call May 4, 2021 8:00 AM ET Company Participants Christine Chiou - Senior Director, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - General Manager, North America Steven Stein - Ch...

Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q1 2021 Earnings Call May 4, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corp (INCY) Q1 2021 Earnings Call Transcript

The following slide deck was published by Incyte Corporation in conjunction with their 2021 Q1 earnings call. For further details see: Incyte Corporation 2021 Q1 - Results - Earnings Call Presentation

Incyte (INCY) shares were choppy during premarket trading after the company posted mixed first-quarter results owing to lower sales for its blockbuster blood disorder treatment Jakafi, hit by seasonal effects and softer patient demand growth due to the ongoing pandemic.Jakafi, ...

Incyte (INCY): Q1 Non-GAAP EPS of $0.67 beats by $0.03; GAAP EPS of $0.24 misses by $0.17.Revenue of $605M (+6.4% Y/Y) misses by $55.72M.Jakafi (ruxolitinib) revenues of $466M (+1% Y/Y) vs. consensus of $516.5M.Reaffirms full year guidance of Jakafi (ruxolitinib) revenues of $2...

Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi ® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billion Pemazyre ® (pemiga...

Incyte (NASDAQ:INCY) is scheduled to announce Q1 earnings results on Tuesday, May 4th, before market open.The consensus EPS Estimate is $0.64 (+122.4% Y/Y) and the consensus Revenue Estimate is $660.72M (+16.2% Y/Y).Over the last 2 years, INCY has beaten EPS estimates 75% of the time and has ...

Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigativ...

Hengrui USA, a unit of Jiangsu Hengrui Pharmaceuticals announced that the FDA has granted the orphan drug designation for Camrelizumab in the treatment of hepatocellular carcinoma ("HCC"), the commonest form of primary liver cancer.An anti-PD-1 antibody, Camrelizumab has won Ch...